読み込み中
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
前日終値
$1.64
+$0.025 · +1.55%
日中の時刻はETです。市場データは遅延する場合があります。
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
日中レンジ
現在 $1.64
52週レンジ
現在 $1.64
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
28
割高
センチメント
45
まちまち
リスク
63
高リスク
モメンタム
32
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
日中レンジ
現在 $1.64
52週レンジ
現在 $1.64
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | — | 5.52万 USD | 14.01万 USD | 16.5万 USD |
| 粗利益 | — | — | 5.52万 USD | 14.01万 USD | 16.5万 USD |
| 研究開発 | 1021.28万 USD | 1079.11万 USD | 1152.06万 USD | 837.73万 USD | 716.42万 USD |
| 販売・一般管理 | 849.79万 USD | 955.95万 USD | 1078.77万 USD | 953.99万 USD | 682.69万 USD |
| 営業費用 | 1871.07万 USD | 2035.06万 USD | 2230.83万 USD | 1791.72万 USD | 1399.12万 USD |
| 受取利息 | 24.44万 USD | 35.71万 USD | 49.42万 USD | 37.54万 USD | 1.25万 USD |
| 減価償却費と償却費 | 9.4万 USD | 8.41万 USD | 8.36万 USD | 6.42万 USD | 1.55万 USD |
| 営業利益 | −1871.07万 USD | −2035.06万 USD | −2225.31万 USD | −1777.7万 USD | −1382.62万 USD |
| 純利益 | −2016.11万 USD | −2041.12万 USD | −2226.75万 USD | −1759.07万 USD | −1389.06万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
